Iain Abbott

Dr

  • 85 Commercial Road, Level 2, Burnet Institute

    3004 Melbourne

    Australia

  • Department of Infectious Diseases, The Alfred and Central Clinical School, Monash University

    Australia

20092020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Based on the background of my clinical experience as an Infectious Diseases Physician and Clinical Microbiologist, I am currently working on a PhD research project in the area of antimicrobial PK/PD in-vitro modelling. I am passionate about tackling the problems of Antimicrobial Resistance and optimising the treatment of complex infection syndromes in vulnerable patients.

External positions

Council, Australasian Society for Infectious Diseases (ASID)

20182019

Infectious Diseases Physician, Alfred Health

2017 → …

Research area keywords

  • Antimicrobial Pharmacology
  • Antimicrobial Resistance
  • Infectious Diseases

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy

Abbott, I. J., van Gorp, E., Wijma, R. A., Meletiadis, J., Mouton, J. W. & Peleg, A. Y., Apr 2020, In : Journal of Microbiological Methods. 171, 11 p., 105861.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections

Abbott, I. J., Dekker, J., van Gorp, E., Wijma, R. A., Raaphorst, M. N., Klaassen, C. H. W., Meletiadis, J., Mouton, J. W. & Peleg, A. Y., 1 Apr 2020, In : Journal of Antimicrobial Chemotherapy. 75, 4, p. 988-996 9 p.

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Oral fosfomycin efficacy with variable urinary exposures following single and multiple doses against enterobacterales: The importance of heteroresistance for growth outcome

Abbott, I. J., Van Gorp, E., Wijma, R. A., Meletiadis, J., Roberts, J. A., Peleg, A. Y. & Mouton, J. W., 1 Mar 2020, In : Antimicrobial Agents and Chemotherapy. 64, 3, 13 p., e01982-19.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Evolution of daptomycin resistance in coagulase-negative staphylococci involves mutations of the essential two-component regulator WALKR

Jiang, J-H., Dexter, C., Cameron, D. R., Monk, I. R., Baines, S. L., Abbott, I. J., Spelman, D. W., Kostoulias, X., Nethercott, C., Howden, B. P. & Peleg, A. Y., 1 Mar 2019, In : Antimicrobial Agents and Chemotherapy. 63, 3, 10 p., e01926-18.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

In vivo acquisition of fosfomycin resistance in Escherichia coli by fosA transmission from commensal flora

Doesschate, T. T., Abbott, I. J., Willems, R. J. L., Top, J., Rogers, M. R. C., Bonten, M. M. & Paganelli, F. L., 1 Dec 2019, In : Journal of Antimicrobial Chemotherapy. 74, 12, p. 3630-3632 3 p., dkz380.

Research output: Contribution to journalArticleOtherpeer-review

Open Access
File
3 Citations (Scopus)